Objective: To report the impact of cladribine on health-related quality of life (QoL) in people with relapsing multiple sclerosis (pwRMS).
Merck KGaA, a leading science and technology company, announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).
Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by clinical or imaging features following approval by the MHRA, meaning more newly diagnosed patients could be eligible for treatment earlier in their disease course.
Introduction: Despite recent progress, currently available therapies for relapsing remitting multiple sclerosis (MS) are only partly effective, and their use is limited by tolerability and safety issues ...
Merck KGaA has announced that it intends to submit its investigational treatment cladribine tablets for the treatment of relapsing multiple...
Merck KGaA announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Merck, a leading science and technology company announced that a resubmission of the New Drug Application (NDA) for cladribine tablets...
Merck KGaA announced the publication of the results of a post hoc analysis of the Phase III CLARITY study of...
Merck KGaA announced that the European Commission (EC) has granted marketing authorization for Mavenclad (Cladribine 10mg Tablets) for the treatment...